Ponvory (Ponesimod) Patent Expiration, LOE Window & CMS Spending
Ponvory (Ponesimod) by Vanda: FDA Orange Book core substance LOE 2032-05-06 (last listed 2044-12-24), 0 AB generics, $8.9M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Vanda |
| FDA Application & Pathway | N213498 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2032-05-06 |
| Last Listed Patent or Exclusivity Date | 2044-12-24 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $8.9M |
| 2024 Medicare Part D Spend | $6.4M |
| 2024 Medicaid Spend | $2.6M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 18.4% 2-yr change) |